ClinicalTrials.gg

Program

fluciclovine F-18

Also written as “18F fluciclovine”, “fluciclovine (18F)” and “18F-fluciclovine PET CT”.

Its studies are mostly in Prostatic Neoplasms · Brain Neoplasms, led by 2 companies.

Furthest: phase 4, since Apr 22, 20265 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bracco41 open or runningphase 4since Apr 22, 2026Jan 15, 2016Dec 31, 2027phase 4 · NCT07569926
GE Healthcare10 open or runningphase 2since Aug 5, 2010Aug 5, 2010none ahead

Also a collaborator on its studies: Precision For Medicine, IND 2 Results and Syne Qua Non.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2010First study: phase 2 study in Prostatic NeoplasmsNew to GE HealthcareGE Healthcare · NCT01176513 · 25 enrolled · United States
  2. Jan 15, 2016Bracco’s first study: phase 3 study in Prostatic NeoplasmsNew to BraccoBracco · NCT02680041 · 221 enrolled · United States
  3. May 27, 2020Phase 2 study in Brain NeoplasmsBracco · NCT04410367 · 23 enrolled · United States
  4. May 27, 2020Phase 3 study in Brain NeoplasmsBracco · NCT04410133 · 151 enrolled · United States
  5. Apr 22, 2026Phase 4 study in Prostatic NeoplasmsBracco · NCT07569926 · 142 planned · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 4 study in Prostatic NeoplasmsBracco · NCT07569926

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07569926Prostatic Neoplasms · United States4RecruitingBraccoDec 31, 2027142
NCT04410367Brain Neoplasms · United States2CompletedBraccoDec 31, 202123
NCT04410133Brain Neoplasms · United States3CompletedBraccoJun 5, 2023151
NCT02680041Prostatic Neoplasms · United States3CompletedBraccoNov 1, 2017221
NCT01176513Prostatic Neoplasms · United States2TerminatedGE HealthcareMar 201225

How it is read

Names in the registry

  • “18F fluciclovine”, 2 entries
  • “fluciclovine (18F)”, 1 entry
  • “18F-fluciclovine PET CT”, 1 entry
  • “GE-148 (18F)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.